Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
Pharmacometric modelling of escalating to subcutaneous semaglutide once-weekly 7.2 mg from 2.0 mg in a STEP UP T2D population: predicting weight reduction and gastrointestinal tolerability
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.